FITC anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
m5/114.15.2 FITC
C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
  • m5/114.15.2 FITC
    C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
107605 50 µg 57€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
107606 500 µg 176€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed
  2. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  3. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  4. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  5. Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed
  6. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  7. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  8. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  9. Yao H, et al. 2023. Front Immunol. 14:1147674. PubMed
  10. Shen Z, et al. 2023. iScience. 26:106572. PubMed
  11. He Y, et al. 2023. Biomolecules. 13:. PubMed
  12. Hsieh MS, et al. 2023. NPJ Vaccines. 8:82. PubMed
  13. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  14. Nguyen T, et al. 2021. STAR Protoc. 2:101004. PubMed
  15. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  16. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  17. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  18. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  19. Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed
  20. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  21. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  22. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  23. Lopez R, et al. 2022. Nat Biotechnol. 40:1360. PubMed
  24. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  25. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  26. Orillion A, et al. 2018. Clin Cancer Res. 24:6383. PubMed
  27. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  28. Sim SL, et al. 2022. Front Endocrinol (Lausanne). 13:957833. PubMed
  29. Tarban N, et al. 2022. Cells. 11:. PubMed
  30. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  31. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  32. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  33. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  34. Du J, et al. 2020. Developmental Cell. 55(6):737-753.e7. PubMed
  35. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  36. Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed
  37. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  38. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  39. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  40. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  41. Dutta S, et al. 2012. Eukaryot Cell. 0.756944444. PubMed
  42. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  43. Hays C, et al. 2020. eLife. 8:e48772.. PubMed
  44. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  45. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  46. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  47. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  48. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  49. Renga G, et al. 2020. Life Sci Alliance. 3:. PubMed
  50. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  51. Wang H et al. 2017. Developmental cell. 40(6):566-582 . PubMed
  52. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  53. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  54. Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed
  55. Qu J, et al. 2018. J Immunol Res. 2018:7519856. PubMed
  56. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  57. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  58. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  59. Mainz RE, et al. 2022. Cells. 11:. PubMed
  60. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  61. Morris E, et al. 2005. J Clin Invest. 115:3093. PubMed
  62. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  63. Tsukasaki M, et al. 2020. Cell Reports. 32(10):108124. PubMed
  64. Hernández–Santos N, et al. 2018. Cell Host Microbe. 1.313194444. PubMed
  65. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  66. Kang SJ, et al. 2022. Food Sci Anim Resour. 42:903. PubMed
  67. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  68. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  69. Reynolds A, et al. 2015. J Immunol. 194:231. PubMed
  70. Kaplan D, et al. 2007. J Exp Med. 204:2545. PubMed
  71. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  72. Zou J, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:983. PubMed
  73. Miki Y, et al. 2016. J Biol Chem. 291: 15588 - 15601. PubMed
  74. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  75. Dobosz E, et al. 2021. Dis Model Mech. :14. PubMed
  76. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  77. Koma T, et al. 2014. J Virol. 88:7178. PubMed
  78. Donaldson B, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0270-1. PubMed
  79. Zhang J, et al. 2018. Sci Rep. 8:2373. PubMed
  80. Hakim R, et al. 2019. Stem Cell Res Ther. 10:115. PubMed
  81. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  82. Vorselen D, et al. 2021. Elife. 10:. PubMed
  83. White C, et al. 2015. J Immunol. 194:697. PubMed
  84. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  85. Kim SH, et al. 2021. Cell Reports. 35(2):108995. PubMed
  86. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  87. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  88. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  89. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  90. Maisel D, et al. 2016. PLoS One. 11: 0159716. PubMed
  91. Steinbach K, et al. 2013. J Immunol. 191:4531. PubMed
  92. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  93. Van Dis E, et al. 2018. Cell Rep. 23:1435. PubMed
  94. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  95. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  96. Banovic T, et al. 2009. J Immunol. 182:912. PubMed
  97. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  98. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  99. Zhao L, et al. 2021. STAR Protocols. 2:100732. PubMed
  100. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  101. Budai Z, et al. 2021. Cells. 10:. PubMed
  102. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  103. Hidaka T, et al. 2016. Nat Immunol. 18:64-73. PubMed
  104. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  105. Wu J, et al. 2019. J Immunol Res. 2019:1749803. PubMed
  106. Kelly SH, et al. 2021. Adv Healthc Mater. 10:e2001614. PubMed
  107. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  108. Wijayadikusumah A, et al. 2017. Amino Acids. 10.1007/s00726-017-2466-6. PubMed
  109. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  110. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  111. Xiao S, Manley N 2010. PLoS One. 5:e15396. PubMed
  112. Grube J, et al. 2022. Cell Death Dis. 13:704. PubMed
  113. Schulz A, et al. 2015. J Biol Chem. 211: 553 - 567. PubMed
  114. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  115. Danne C et al. 2017. Cell host & microbe. 22(6):733-745 . PubMed
  116. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  117. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  118. Nicholls J, et al. 2021. Front Cell Dev Biol. 9:737880. PubMed
  119. Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed
  120. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  121. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
  122. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  123. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  124. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  125. Al-Zaeed N, et al. 2021. Cell Death Dis. 12:611. PubMed
  126. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  127. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
  128. Harberts E, et al. 2015. J Immunol. 194:3127. PubMed
  129. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  130. Park CJ, et al. 2020. Cell Reports. 31(2):107496.. PubMed
  131. Deets KA, et al. 2021. Elife. 10:. PubMed
  132. Spanier J, et al. 2016. Nat Commun. 7:11804. PubMed
  133. Dong S, et al. 2007. Int Immunopharmacol. 7:725. PubMed
RRID
AB_313320 (BioLegend Cat. No. 107605)
AB_313320 (BioLegend Cat. No. 107606)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 4    Revision Date: 10/30/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account